| Bioactivity | Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research[1]. |
| Invitro | Betifisolimab (MSB-2311) 是一种人源化 PD-L1 抗体，具有独特的 pH 依赖性抗原结合特性，可实现肿瘤内循环并增强肿瘤渗透[1]。 |
| Name | Betifisolimab |
| CAS | 2460539-60-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xichun Hu, et al. MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients. Journal of Clinical Oncology 38, no. 15_suppl. |